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EDITORIAL
Transurethral resection of the prostate: reaffirming the
gold standard
Symptomatic benign prostatic hyperplasia (BPH)
occurs in one third of men over the age of 65 years.
With an increase in the ageing population of Hong
Kong, the number of men suffering from BPH is
expected to increase in the next decade. These men
will live longer, enjoy a better quality of life, and
receive more comprehensive medical care for the
remainder of their active lives than the previous
generation. The associated costs of managing BPH
will consequently and inevitably increase substantially.
With finite health care resources, the cost-effective
management of BPH will be a major challenge.
The clinical manifestations of BPH are felt to
arise from bladder outlet obstruction. Medical and
surgical intervention aims to relieve the obstruction.
Since the 1990s, the medical management of BPH
has improved dramatically and resulted in a sharp
decrease in the number of symptomatic patients
treated surgically. Prostatectomy and minimally inva-
sive therapies resect or ablate the obstructing tissue.
The associated morbidity of minimally invasive ther-
apies is less compared with that of prostatectomy, but
such procedures are also less effective.
The study1 published in this issue of the Hong Kong
Medical Journal offers some insight into the current
surgical management of BPH. Several minimally in-
vasive therapies have been investigated in Hong Kong
but have not been subjected to rigorous randomised
controlled trials (RCTs). Nonetheless, it is only through
properly designed clinical investigations that the true
therapeutic benefits of these treatments can be defined.
Interstitial thermal ablation techniques (trans-
urethral microwave thermotherapy [TUMT], trans-
urethral needle ablation [TUNA], and interstitial laser
coagulation) using various sources of energy to induce
coagulative necrosis and delayed prostate shrinkage
have several advantages: minimal or no bleeding,
avoidance of transurethral resection of the prostate
(TURP) syndrome, and need for less anaesthesia.
Patients can also be treated on an out-patient basis.
Unfortunately, the development of postoperative
oedema and delayed sloughing of tissue as a conse-
quence of the energy-induced coagulative necrosis
lead to prolonged urinary obstruction, and patients may
require catheterization for up to 3 weeks after treatment.
Some of these techniques have a high re-treatment
rate (up to 40%) for recurrent obstruction over the
next few years and further more aggressive therapy is
required.2 Many of these techniques have thus been
largely abandoned.
Minimally invasive therapies have evolved based
on the principle of prostatectomy with immediate
removal of the obstructing tissue. Such therapies
include transurethral vaporisation of the prostate
(TUVP), Holmium laser resection of the prostate, and
photoselective vaporisation of the prostate (PVP)
with KTP laser. Transurethral vaporisation is associ-
ated with a high rate of postoperative irritative void-
ing symptoms, dysuria, urinary retention, and need for
unplanned secondary catheterization as a result of
postoperative oedema and delayed sloughing of issue.
The same occurs following visual laser ablation of
the prostate (VLAP) and both procedures (TUVP and
VLAP) have been largely abandoned in Hong Kong.
Holium laser resection of the prostate attempts to
mimic standard TURP by excising and removing pieces
of prostatic tissue transurethrally, thus gradually creat-
ing a cavity. Development of a mechanical tissue
morcellator has improved the handling of the excised
prostatic tissue and has made resection of larger pieces
of tissue feasible. Nonetheless, the procedure takes
longer operating time than the standard TURP (83±38
minutes vs 58±32 minutes, respectively),3 and has not
been widely adopted by urologists as it is technically
challenging. Furthermore, Holmium laser equipment
is not widely available, and the cost of purchasing such
equipment may prohibit its widespread use.
KTP laser has been used in the last few years for
PVP and results in an immediate TURP-like cavity with
good haemostasis and minimal scarring. As the tissue
is completely vaporised, postoperative histological
analysis to rule out prostatic cancer cannot be per-
formed unfortunately. Preliminary results from the first
multicentre prospective trial4 have shown it to be a
safe, effective means of achieving symptomatic and
urodynamic relief of BPH symptoms. Like many of
the surgical alternatives to TURP, this procedure shows
early promise and represents the latest evolutionary
development in laser prostatectomy. Only randomised
comparisons with TURP will confirm whether it
presents a worthy alternative or is ‘simply a young
pretender to the throne’.
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Transurethral vaporisation-resection of the
prostate (TUVRP) is a modified standard TURP, in
which a thick electric loop is used in conjunction
with increased electrosurgical settings. It has the
advantage of better haemostasis (better vision and
easier operation for the surgeons and safer operation
for the patients) and less complications secondary to
intra-operative bleeding and fluid absorption. The re-
sults of a prospective randomised study5 of TUVRP
versus TURP in 136 patients with acute urinary
retention secondary to BPH concluded that TUVRP
compared favourably with standard TURP in terms of
safety and efficacy. Changes in sodium levels were
statistically significant, in favour of TUVRP, but not
clinically significant. Blood transfusion was required
in three patients in the TURP group and the catheteri-
zation time was longer.
Plasma kinetic vaporisation of the prostate (Gyrus
system) utilises bipolar rather than monopolar cur-
rents and saline instead of glycine for irrigation. The
risk of TURP syndrome is thus minimised. Prelimin-
ary results of a single-blind RCT of Gyrus electro-
vaporisation versus TURP revealed that improve-
ments in symptom score and flow rates at 1 year
were similar.6 There was no difference in the re-
quirement for irrigation, haematocrit of the efflu-
ent, or duration of hospital stay. Nonetheless, the
Gyrus group had a recatheterization rate of 30%,
6 times that of TURP. Gyrus electrovaporisation does
not appear to offer any advantages over conventional
TURP.
For patients in whom surgery or anaesthesia is
contraindicated, prostatic stenting can provide a
temporary or permanent solution for bladder outlet
obstruction caused by BPH. Insertion of prostatic
stents is generally easy, immediately effective, and
usually performed on an out-patient basis under
monitored anaesthetic care or regional anaesthesia. To
date, most patients treated with prostatic stents pre-
sented with urinary retention and were not sufficiently
fit for other procedures. The majority have been able
to void successfully after stent placement7 and did not
need an indwelling urethral catheter.
Transurethral ethanol ablation of the prostate in-
duces cell lysis and tissue necrosis by injecting an-
hydrous alcohol into the prostate. Initial evaluation
(unpublished) 10 years ago on a canine prostate model
revealed intraprostatic necrosis. The technique was
introduced into clinical study in 20048 but remains an
investigative technique that should not be offered out-
side the framework of clinical trials.
Despite the increase in the number of surgical
alternatives such as TUMT, TUNA, and various
forms of laser prostatectomy, TURP and its modified
form (TUVRP) remain the gold standard surgical
treatment for obstruction due to BPH. Although
minimally invasive therapies have not replaced TURP,
they are accepted alternatives. They are associated with
less morbidity than transurethral surgery due to fewer
bleeding and anaesthetic problems. The less invasive
alternatives are nonetheless not as effective as TURP.
It is thus appropriate to consider them as alternatives
to and not a substitute for TURP. The future goal is to
achieve the efficacy of prostatectomy and reduced
morbidity with the less invasive techniques.
The standard surgical procedures of TURP and
TUVRP produce the most significant long-term symp-
tom improvement. The outcome is nevertheless un-
satisfactory for up to 30% of patients. The optimal
treatment of BPH requires an improved understand-
ing of the pathophysiology and natural history of the
disease as well as new technology. Urologists are
presently engaged in studies to better define these
fundamental aspects of the disease process.
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